Anti-C1q Antibodies for Classical Complement and Synapse Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for antibodies that specifically bind to and neutralize the biological activities of complement factor C1q, which is implicated in excessive synapse loss and neurodegenerative diseases such as Alzheimer's, amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease, as existing complement neutralizing antibodies like Eculizumab are limited in scope.
Innovation Solution
Development of anti-C1q antibodies, such as the murine monoclonal antibody M1 and its progeny, which specifically bind to C1q epitopes and neutralize its biological activities, including C1q binding to autoantibodies, activation of the classical complement pathway, and synapse loss, with high affinity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing complement neutralizing antibodies like Eculizumab are used, then terminal complement activation pathway is inhibited, but scope of neutralization is limited and does not cover C1q-mediated synapse loss
Solution Approach 1:
The invention segments the complement neutralization approach by developing separate antibodies for different complement factors. Instead of relying on a single antibody like Eculizumab that only targets C5, the patent creates distinct antibodies (anti-C1q, anti-C3) for different stages of complement activation, thereby expanding the scope of neutralization while maintaining reliability for each specific target.
Solution Approach 2:
The anti-C1q antibody serves multiple functions: it neutralizes C1q binding to autoantibodies, blocks activation of the classical complement pathway, and prevents synapse loss. This multi-functionality addresses the limitation of existing antibodies that have narrow scopes of action.
2Reliability
If anti-C1q antibodies are developed to neutralize C1q activities, then synapse loss is reduced and neurodegenerative disease progression is slowed, but specificity and potency must be optimized to avoid off-target effects
Solution Approach 1:
The anti-C1q antibody is designed with specific binding characteristics that target particular epitopes on C1q involved in synapse loss and complement activation. The antibody exhibits different binding affinities for different C1q epitopes, demonstrating local quality in its binding properties to achieve selective neutralization of harmful C1q activities while maintaining specificity.
3Power
If high affinity binding to C1q is achieved, then neutralization potency is increased, but risk of off-target binding and unwanted immune activation increases
Solution Approach 1:
The invention converts the potential harm of high-affinity binding into a benefit by carefully selecting and engineering antibody variants that achieve high potency against pathogenic C1q complexes (such as C1q bound to autoantibodies or synapses) while maintaining selectivity. The high affinity is directed specifically at pathological targets rather than healthy tissues, transforming what could be a source of off-target effects into enhanced therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-C1q antibodies effectively neutralize C1q activities, reducing synapse loss and potentially slowing neurodegenerative disease progression, with high specificity and potency, and can be administered to treat a range of diseases including neurodegenerative, inflammatory, and autoimmune disorders.
Implementation Method 1
anti-C1q antibodies, such as the murine monoclonal antibody M1 and its progeny, which specifically bind to C1q epitopes and neutralize its biological activities
Data Source
AI summary
The present invention provides anti-C1q antibodies and methods of using the same.